Robert J. March, M.D.

Dr. Robert J. March is committed to providing his patients with excellent care in hematology and medical oncology in Rockland County and surrounding areas. Board-certified by the American Board of Internal Medicine for Internal Medicine, Medical Oncology, and Hematology, Dr. March is currently in private practice at Hematology Oncology Associates of Rockland, P.C. in Nyack, New York.

After receiving his Bachelors of Arts in Biology and Psychology at New York University, Dr. March received his Doctor of Medicine at the American University of the Caribbean in Montserrat, British West Indies. His post-graduate training included an Internship in Medicine followed by a Residency in Medicine at Bronx V.A Medical Center at Mount Sinai Hospital in New York, NY. He then joined a fellowship in Hematology and Medical Oncology at New York Medical College of Westchester County Medical Center in Valhalla, NY.

Current hospital affiliations of Dr. March include Nyack Hospital in Nyack and Good Samaritan Hospital in Suffern, where he is an attending physician in Hematology and Medical Oncology.

In addition to his clinical success, Dr. March is active in biomedical research and has published numerous articles related to his fields of hematology and oncology. He has also received awards from the American Cancer Society for Appreciation and for Breast Health Partnership. Dr. March is a member of several professional organizations, including the American Society of Clinical Oncology, the American Society of Hematology, the American Society of Internal Medicine, the American Medical Association, and many others.

Publications:

• Herbert, V., March, R., et al. “Vitamin B12 Analogue Levels Tend to Rise as Cobalamine Deficiency Develops With Cessation of Therapy in Pernicious Anemia”, Blood 68: November, 1986
• Feldman, E., March, R., et aI. “Phase II Trial of Bisanterene in Relapsed or Refractory Acute Non-Lymphocytic Leukemia (ANLL) and Blastic Chronic Myelogenous Leukemia”, ASH, December, 1989
• March, R., et aI. “Hypercalcemia of Malignancy Associated With Adenocarcinoma of the Rectum: Case Report and Review of the Literature”, Anticancer Research 11:2029-2030, 1991
• Savage, D.G., Cohen, N., Hesdorffer, C.S., Heitian, Martin W., Garrett, T.J., Bar, M., DelPrete, S., March, R., Lonberg, M., Talbot, S., Mears, G.,Flamm, M., Taub, R.N. and Nichols, Gwen, “Combined Fludarabine and Rituxamab for Low Grade Lymphoma and Chronic Lymphocytic Leukemia”, Leukemia and Lymphoma, 2003, Vol. 44(3), pp. 477-481
• Phase 2 Trial of Talabostat and Docetaxel in Patients with Stage IIIB/IV NSCLC.C. Cunningham¹, D. Richards², R. Salgia³, R. Leonard⁴, R. Raju⁵, J. Arseneau⁶, S. Packer⁷,R. March⁸, S. Anthony⁹, B. Berman¹⁰, Z. Yang¹¹, L. Gregoire¹², E. Haltom¹², M. J. Uprichard¹²; ¹Mary Crowley Medical Research Center, Dallas, TX; ²Tyler Cancer Center, Tyler, TX; ³University of Chicago, Chicago, IL; ⁴Van Elslander Cancer Center, Grosse Pointe Woods, MI; ⁵Dayton Oncology & Hematology, Kettering, OH; ⁶New York Oncology Hematology, Albany, NY; ⁷Mount Sinai School of Medicine, New York, NY; ⁸USB Cancer Center, Nyack, NY; ⁹Cancer Care Northwest, Spokane, WA; ¹⁰Cancer Center of Florida, Ocoee, FL; ¹¹Kendle International Inc. Cincinnati, OH, ¹²Point Therapeutics, Boston, MA.: AACR-EORTC-NCI International Conference on Molecular Targets and Cancer Therapeutics, November 2005.
• March, R, Mirtsching, B. Modi, S., et al, “ A Phase II Study of XL999 in Patients with NSCLC” Abstract 18112, ASCO 2007
• Cripe, RL, Stadler, M. Wertheim, M. Eisenberg, P., March, R., McGuire, W., et.al. “Integrated Report of the Phase II Experience with XL-999 Administered IV to Patients with Non-Small Cell Lung Cancer, Renal Cell Cancer, Metastatic Colorectal Cancer, Recurrent Ovarian Cancer, Acute Myelogenous Leukemia and Multiple Myeloma” Poster 35, ASCO 2007